{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:37:42Z","timestamp":1794573462395,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7953","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    T\u2009cell receptors (TCRs) enable T\u2009cells to specifically recognize mutations in cancer cells\n                    <jats:sup>1\u20133<\/jats:sup>\n                    . Here we developed a clinical-grade approach based on CRISPR\u2013Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes\n                    <jats:italic>TRAC<\/jats:italic>\n                    (which encodes TCR\u03b1) and\n                    <jats:italic>TRBC<\/jats:italic>\n                    (which encodes TCR\u03b2). We also inserted into the\n                    <jats:italic>TRAC<\/jats:italic>\n                    locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T\u2009cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen\u2013HLA capture reagents. Sixteen patients with different refractory solid cancers received up to three distinct neoTCR transgenic cell products. Each product expressed a patient-specific neoTCR and was administered in a cell-dose-escalation, first-in-human phase\u2009I clinical trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970382\">NCT03970382<\/jats:ext-link>\n                    ). One patient had grade\u20091 cytokine release syndrome and one patient had grade\u20093 encephalitis. All participants had the expected side effects from the lymphodepleting chemotherapy. Five patients had stable disease and the other eleven had disease progression as the best response on the therapy. neoTCR transgenic T\u2009cells were detected in tumour biopsy samples after infusion at frequencies higher than the native TCRs before infusion. This study demonstrates the feasibility of isolating and cloning multiple TCRs that recognize mutational neoantigens. Moreover, simultaneous knockout of the endogenous TCR and knock-in of neoTCRs using single-step, non-viral precision genome-editing are achieved. The manufacture of neoTCR engineered T\u2009cells at clinical grade, the safety of infusing up to three gene-edited neoTCR T\u2009cell products and the ability of the transgenic T\u2009cells to traffic to the tumours of patients are also demonstrated.\n                  <\/jats:p>","DOI":"10.1038\/s41586-022-05531-1","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T12:04:18Z","timestamp":1668081858000},"page":"687-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":283,"title":["Non-viral precision T\u2009cell receptor replacement for personalized cell therapy"],"prefix":"10.1038","volume":"615","author":[{"given":"Susan P.","family":"Foy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Bota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-1294","authenticated-orcid":false,"given":"Theresa","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Stawiski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dalmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Heeringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sennino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Bethune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Gunturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Litterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boi Bryant","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonsus H. C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-4432","authenticated-orcid":false,"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Skrdlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Yi-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ventura","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhamini","family":"Purandare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Moot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Stallings-Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-3320","authenticated-orcid":false,"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-0977","authenticated-orcid":false,"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-2230","authenticated-orcid":false,"given":"Sylvia M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8723-8190","authenticated-orcid":false,"given":"David","family":"Baltimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-4385","authenticated-orcid":false,"given":"James R.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Franzusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie J.","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"5531_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"5531_CR2","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"5531_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"5531_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433\u2013438 (2016).","journal-title":"Nat. Med."},{"key":"5531_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"5531_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"5531_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"5531_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"5531_CR9","doi-asserted-by":"publisher","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science https:\/\/doi.org\/10.1126\/science.abl5447 (2022).","DOI":"10.1126\/science.abl5447"},{"key":"5531_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"5531_CR11","doi-asserted-by":"publisher","first-page":"D423","DOI":"10.1093\/nar\/gku1161","volume":"43","author":"J Robinson","year":"2015","unstructured":"Robinson, J. et al. The IPD and IMGT\/HLA database: allele variant databases. Nucleic Acids Res. 43, D423\u2013D431 (2015).","journal-title":"Nucleic Acids Res."},{"key":"5531_CR12","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-21-0269","volume":"9","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum, U., Dumbrava, E. I., Biter, A. B., Haymaker, C. L. & Hong, D. S. Engineered T-cell receptor T cells for cancer immunotherapy. Cancer Immunol. Res. 9, 1252\u20131261 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"5531_CR13","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.celrep.2019.07.106","volume":"28","author":"S Peng","year":"2019","unstructured":"Peng, S. et al. Sensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood. Cell Rep. 28, 2728\u20132738.e7 (2019).","journal-title":"Cell Rep."},{"key":"5531_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299\u2013308 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"5531_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"5531_CR16","doi-asserted-by":"publisher","first-page":"e20211530","DOI":"10.1084\/jem.20211530","volume":"219","author":"SA Oh","year":"2022","unstructured":"Oh, S. A. et al. High-efficiency nonviral CRISPR\/Cas9-mediated gene editing of human T cells using plasmid donor DNA. J. Exp. Med. 219, e20211530 (2022).","journal-title":"J. Exp. Med."},{"key":"5531_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"5531_CR18","doi-asserted-by":"publisher","first-page":"100374","DOI":"10.1016\/j.xcrm.2021.100374","volume":"2","author":"TR Muller","year":"2021","unstructured":"Muller, T. R. et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep. Med. 2, 100374 (2021).","journal-title":"Cell Rep. Med."},{"key":"5531_CR19","doi-asserted-by":"publisher","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero, E. et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci. Transl Med. 14, eabg8027 (2022).","journal-title":"Sci. Transl Med"},{"key":"5531_CR20","doi-asserted-by":"publisher","unstructured":"Puig-Saus, C. et al. Landscape analysis of neoepitope-specific T cell responses to immunotherapy. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-NG11 (2020).","DOI":"10.1158\/1538-7445.AM2020-NG11"},{"key":"5531_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"5531_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"5531_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"5531_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","volume":"129","author":"P Malekzadeh","year":"2019","unstructured":"Malekzadeh, P. et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest. 129, 1109\u20131114 (2019).","journal-title":"J. Clin. Invest."},{"key":"5531_CR25","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","volume":"3","author":"BY Jin","year":"2018","unstructured":"Jin, B. Y. et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 3, e99488 (2018).","journal-title":"JCI Insight"},{"key":"5531_CR26","doi-asserted-by":"publisher","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","volume":"9","author":"JP Sanderson","year":"2020","unstructured":"Sanderson, J. P. et al. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology 9, 1682381 (2020).","journal-title":"Oncoimmunology"},{"key":"5531_CR27","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","volume":"21","author":"LM Draper","year":"2015","unstructured":"Draper, L. M. et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin. Cancer Res. 21, 4431\u20134439 (2015).","journal-title":"Clin. Cancer Res."},{"key":"5531_CR28","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L. et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 75, 3853\u20133864 (2015).","journal-title":"Cancer Res."},{"key":"5531_CR29","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"5531_CR30","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.4049\/jimmunol.1102609","volume":"188","author":"S Mujib","year":"2012","unstructured":"Mujib, S. et al. Antigen-independent induction of Tim-3 expression on human T cells by the common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 188, 3745\u20133756 (2012).","journal-title":"J. Immunol."},{"key":"5531_CR31","doi-asserted-by":"publisher","first-page":"1744946","DOI":"10.1080\/2162402X.2020.1744946","volume":"9","author":"I Shevchenko","year":"2020","unstructured":"Shevchenko, I. et al. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncoimmunology 9, 1744946 (2020).","journal-title":"Oncoimmunology"},{"key":"5531_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"5531_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"5531_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdy003","volume":"29","author":"S Venkatesan","year":"2018","unstructured":"Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563\u2013572 (2018).","journal-title":"Ann. Oncol."},{"key":"5531_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609, 369\u2013374 (2022).","journal-title":"Nature"},{"key":"5531_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704\u2013712 (2015).","journal-title":"Cancer Discov."},{"key":"5531_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e11 (2017).","journal-title":"Cell"},{"key":"5531_CR38","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1200\/JCO.18.02424","volume":"37","author":"SL Doran","year":"2019","unstructured":"Doran, S. L. et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study. J. Clin. Oncol. 37, 2759\u20132768 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5531_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"5531_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"5531_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41590-020-0628-2","volume":"21","author":"K Schober","year":"2020","unstructured":"Schober, K. et al. Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection. Nat. Immunol. 21, 434\u2013441 (2020).","journal-title":"Nat. Immunol."},{"key":"5531_CR42","doi-asserted-by":"publisher","unstructured":"Wermke, M. et al. Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses\u2014clinical update on the ACTengine\u00ae IMA203 trial. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.959 (2021).","DOI":"10.1136\/jitc-2021-SITC2021.959"},{"key":"5531_CR43","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1016\/j.annonc.2022.07.861","volume":"33","author":"DS Hong","year":"2022","unstructured":"Hong, D. S. et al.Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors. Ann. Oncol. 33, S331\u2013S355 (2022).","journal-title":"Ann. Oncol."},{"key":"5531_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807\u2013815 (2012).","journal-title":"Nat. Med."},{"key":"5531_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"5531_CR46","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165\u20131169 (2016).","journal-title":"Science"},{"key":"5531_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","volume":"24","author":"MO Li","year":"2006","unstructured":"Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A. Transforming growth factor-\u03b2 regulation of immune responses. Annu. Rev. Immunol. 24, 99\u2013146 (2006).","journal-title":"Annu. Rev. Immunol."},{"key":"5531_CR48","doi-asserted-by":"publisher","first-page":"eabj4008","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).","journal-title":"Science"},{"key":"5531_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"5531_CR50","doi-asserted-by":"publisher","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1303.3997 (2013).","DOI":"10.48550\/arXiv.1303.3997"},{"key":"5531_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"5531_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"5531_CR53","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"5531_CR54","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108 (2016).","journal-title":"Nucleic Acids Res."},{"key":"5531_CR55","doi-asserted-by":"publisher","first-page":"11.14.1","DOI":"10.1002\/0471250953.bi1114s51","volume":"51","author":"A Dobin","year":"2015","unstructured":"Dobin, A. & Gingeras, T. R. Mapping RNA-seq reads with STAR. Curr. Protoc Bioinformatics 51, 11.14.1\u201311.14.19 (2015).","journal-title":"Curr. Protoc Bioinformatics"},{"key":"5531_CR56","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"5531_CR57","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"5531_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."},{"key":"5531_CR59","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396\u2013398 (2014).","journal-title":"Nat. Methods"},{"key":"5531_CR60","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 8, 174\u2013183 (2018).","journal-title":"Cancer Discov."},{"key":"5531_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/1538-7445.AM2020-1334","volume":"80","author":"RP Power","year":"2020","unstructured":"Power, R. P. et al. A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome. Cancer Res. 80, 1334 (2020).","journal-title":"Cancer Res."},{"key":"5531_CR62","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"5531_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12859-018-2234-y","volume":"19","author":"M Diaz-Gay","year":"2018","unstructured":"Diaz-Gay, M. et al. Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinformatics 19, 224 (2018).","journal-title":"BMC Bioinformatics"},{"key":"5531_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"5531_CR65","doi-asserted-by":"publisher","unstructured":"Smith, C., Ma, Y., Campbell, K. M., Pan, Z. & Stawiski, E. Uncovering HLA loss of heterozygosity in cancer for the improvement of personalized neoTCR immunotherapy with PACT-ESCAPE. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-1213 (2022).","DOI":"10.1158\/1538-7445.AM2022-1213"},{"key":"5531_CR66","first-page":"D948","volume":"48","author":"J Robinson","year":"2020","unstructured":"Robinson, J. et al. IPD-IMGT\/HLA database. Nucleic Acids Res. 48, D948\u2013D955 (2020).","journal-title":"Nucleic Acids Res."},{"key":"5531_CR67","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873\u2013881 (2020).","journal-title":"Nat. Cancer"},{"key":"5531_CR68","doi-asserted-by":"publisher","first-page":"27105","DOI":"10.1074\/jbc.M303716200","volume":"278","author":"L Lybarger","year":"2003","unstructured":"Lybarger, L. et al. Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J. Biol. Chem. 278, 27105\u201327111 (2003).","journal-title":"J. Biol. Chem."},{"key":"5531_CR69","doi-asserted-by":"publisher","first-page":"D413","DOI":"10.1093\/nar\/gku1056","volume":"43","author":"MP Lefranc","year":"2015","unstructured":"Lefranc, M. P. et al. IMGT\u00ae, the international ImMunoGeneTics information system\u00ae 25 years on. Nucleic Acids Res. 43, D413\u2013D422 (2015).","journal-title":"Nucleic Acids Res."},{"key":"5531_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2144\/000114525","volume":"62","author":"MT Bethune","year":"2017","unstructured":"Bethune, M. T., Comin-Anduix, B., Hwang Fu, Y. H., Ribas, A. & Baltimore, D. Preparation of peptide\u2013MHC and T-cell receptor dextramers by biotinylated dextran doping. BioTechniques 62, 123\u2013130 (2017).","journal-title":"BioTechniques"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05531-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T09:14:54Z","timestamp":1679476494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05531-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":70,"journal-issue":{"issue":"7953","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["5531"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-05531-1","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P.F., K.J., T.H., Z.P., E.S., Y.M., W.L., S.P., C.L.W., B.Y., O.D., K.H., B.S., A.C., M.T.B., I.M., W.W., M.K., S.G., E.H., A.H., D.\u2009An, A.J.L., B.B.Q., C.S., D.\u2009Anaya, L.S., E.Y.-H.H., V.M., J.M., L.D., B.P., R.M., M.C.Y., R.F., A.S., T.S.-S., A.F., A.V.R. and S.J.M. were employees of PACT Pharma during the conduct of this work. S.P., M.T.B., D.B., J.R.H. and A.R. are scientific co-founders of PACT Pharma. K.M.C. has received consulting fees from PACT Pharma and Tango Therapeutics and is a shareholder in Geneoscopy. D.Y.O. has received research support from Merck, PACT Pharma, the Parker Institute for Cancer Immunotherapy, Poseida Therapeutics, TCR2 Therapeutics, Roche\/Genentech and Nutcracker Therapeutics. B.C. has advisory roles with the following companies: Iovance Biotherapeutics, IDEAYA Biosciences, Sanofi, OncoSec, Nektar, Genentech, Novartis and Instil Bio. D.Y.O. has also received research funding from the following companies: Iovance Biotherapeutics, Bristol-Myers Squibb, Macrogenics, Daiichi Sankyo, Merck, Karyopharm Therapeutics, Infinity Pharmaceuticals, Advenchen Laboratories, Idera, Neon Therapeutics, Xencor, Compugen, PACT Pharma, RAPT Therapeutics, Immunocore, Lilly, IDEAYA Biosciences, Tolero Pharmaceuticals, Ascentage Pharma, Novartis, Atreca, Replimune, Instil Bio, Trisalus and Kinnate. J.A.S. reports honorarium from Iovance, Apixogen, Jazz Pharm, and research with BMS, PACT Pharma and Corvus. A.J.S. reports consulting or advising roles to J&J, KSQ Therapeutics, BMS, Enara Bio, Perceptive Advisors, Heat Biologics and Iovance Biotherapeutics. Research funding: GSK (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS (Inst), Harpoon Therapeutics (Inst). A.R. has received honoraria from consulting with Amgen, CStone, Merck, and Vedanta, is or has been a member of the scientific advisory board and holds stock in Advaxis, Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, ImmuneSensor, Inspirna, Isoplexis, Kite-Gilead, Lutris, MapKure, Merus, PACT Pharma, Pluto, RAPT, Synthekine and Tango, has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. D.A.B., A.H.C.N., Y.L., M.A., Y.Y. and S.M.L. report no conflicts of interest for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}